NewLink Genetics Corp. and Merck have been awarded a $30 million Biomedical Advanced Research and Development Authority (BARDA) contract to support the manufacture and development of its investigational rVSV-EBOV (Ebola) vaccine candidate, including clinical development through a new 330-person Phase Ib study.   The vaccine candidate, initially developed by the Public Health Agency of Canada (PHAC), is being developed under an exclusive licensing and collaboration agreement between NewLink Genet...